-
1.发明授权Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy 有权氨基茚满衍生物，含有它们的药物组合物及其在治疗中的应用公开(公告)号：US09227930B2
公开(公告)日：2016-01-05
申请号：US14317104
申请日：2014-06-27
Applicant: ABBOTT LABORATORIES , ABBVIE DEUTSCHLAND GMBH & CO KG
Inventor： Frauke Pohlki , Udo Lange , Wilhelm Amberg , Michael Ochse , Berthold Behl , Charles W. Hutchins
IPC: A61K31/135 , C07C211/27 , C07C311/14 , C07C311/10 , C07D205/04 , C07D231/18 , C07D403/12 , C07D233/84
CPC classification number: C07C311/14 , C07C311/10 , C07C2601/02 , C07C2602/08 , C07D205/04 , C07D231/18 , C07D233/84 , C07D403/12
Abstract: The present invention relates to aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminoindane derivatives, and the use of such aminoindane derivatives for therapeutic purposes. The aminoindane derivatives are GlyT1 inhibitors.
Abstract translation: 本发明涉及式（I）的氨基茚满衍生物或其生理上耐受的盐。 本发明涉及包含这种氨基茚满衍生物的药物组合物以及这种氨基茚满衍生物用于治疗目的的用途。 氨基茚满衍生物是GlyT1抑制剂。
-
2.发明授权
公开(公告)号：US09067871B2
公开(公告)日：2015-06-30
申请号：US14031265
申请日：2013-09-19
Applicant: ABBVIE DEUTSCHLAND GMBH & CO KG , ABBOTT LABORATORIES
Inventor： Wilhelm Amberg , Michael Ochse , Udo Lange , Andreas Kling , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles W. Hutchins
IPC: A61K31/16 , C07C215/70 , C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07D205/04 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D275/02 , C07D295/096 , C07D305/08 , C07D333/34 , C07D403/12 , C07F7/08 , C07D401/12 , C07D409/12
CPC classification number: C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/13 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07C2601/02 , C07C2601/04 , C07C2602/10 , C07D205/04 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D265/30 , C07D275/02 , C07D295/096 , C07D295/135 , C07D305/08 , C07D333/34 , C07D401/12 , C07D403/12 , C07D409/12 , C07F7/081
Abstract: The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.
-
3.发明授权Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy 有权苯烷基胺衍生物，含有它们的药物组合物及其在治疗中的用途
公开(公告)号：US09238619B2
公开(公告)日：2016-01-19
申请号：US14282712
申请日：2014-05-20
Applicant: AbbVie Deutschland GmbH & Co. KG , Abbott Laboratories
Inventor： Frauke Pohlki , Udo Lange , Wilhelm Amberg , Michael Ochse , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles W. Hutchins , Sean Turner
IPC: A61K31/135 , C07C211/25 , C07C311/06 , C07C311/04 , C07C311/05 , C07C311/10 , C07D205/04 , C07D207/08 , C07D207/267 , C07D231/18 , C07D233/42 , C07D295/135 , C07D401/12 , C07D403/12 , C07D233/84
CPC classification number: C07C311/06 , C07C311/04 , C07C311/05 , C07C311/10 , C07C2601/02 , C07C2601/04 , C07D205/04 , C07D207/08 , C07D207/267 , C07D231/18 , C07D233/42 , C07D233/84 , C07D295/135 , C07D401/12 , C07D403/12
Abstract: The present invention relates to phenalkylamine derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such phenalkylamine derivatives, and the use of such phenalkylamine derivatives for therapeutic purposes. The phenalkylamine derivatives are GlyT1 inhibitors.
Abstract translation: 本发明涉及式（I）的苯烷基胺衍生物或其生理上耐受的盐。 本发明涉及包含这种苯烷基胺衍生物的药物组合物，以及这种苯烷基胺衍生物用于治疗目的的用途。 酚烷基胺衍生物是GlyT1抑制剂。
-
4.发明申请AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权氨基丹衍生物，含有它们的药物组合物及其在治疗中的使用
公开(公告)号：US20140309206A1
公开(公告)日：2014-10-16
申请号：US14317104
申请日：2014-06-27
Applicant: ABBOTT LABORATORIES , ABBVIE DEUTSCHLAND GMBH & CO KG
Inventor： Frauke Pohlki , Udo Lange , Wilhelm Amberg , Michael Ochse , Berthold Behl , Charles W. Hutchins
IPC: C07C311/14 , C07D231/18 , C07D205/04 , C07D403/12 , C07C311/10 , C07D233/84
CPC classification number: C07C311/14 , C07C311/10 , C07C2601/02 , C07C2602/08 , C07D205/04 , C07D231/18 , C07D233/84 , C07D403/12
Abstract: The present invention relates to aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminoindane derivatives, and the use of such aminoindane derivatives for therapeutic purposes. The aminoindane derivatives are GlyT1 inhibitors.
Abstract translation: 本发明涉及式（I）的氨基茚满衍生物或其生理上耐受的盐。 本发明涉及包含这种氨基茚满衍生物的药物组合物以及这种氨基茚满衍生物用于治疗目的的用途。 氨基茚满衍生物是GlyT1抑制剂。
-
5.发明申请PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权PHENALKYLAMINE衍生物，含有它们的药物组合物及其在治疗中的使用
公开(公告)号：US20140256701A1
公开(公告)日：2014-09-11
申请号：US14282712
申请日：2014-05-20
Applicant: AbbVie Deutschland GmbH & Co. KG , Abbott Laboratories
Inventor： Frauke Pohlki , Udo Lange , Wilhelm Amberg , Michael Ochse , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles W. Hutchins , Sean Turner
IPC: C07D403/12 , C07D231/18 , C07D401/12 , C07D295/135 , C07C311/05 , C07C311/06 , C07D233/84 , C07C311/10
CPC classification number: C07C311/06 , C07C311/04 , C07C311/05 , C07C311/10 , C07C2601/02 , C07C2601/04 , C07D205/04 , C07D207/08 , C07D207/267 , C07D231/18 , C07D233/42 , C07D233/84 , C07D295/135 , C07D401/12 , C07D403/12
Abstract: The present invention relates to phenalkylamine derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such phenalkylamine derivatives, and the use of such phenalkylamine derivatives for therapeutic purposes. The phenalkylamine derivatives are GlyT1 inhibitors.
Abstract translation: 本发明涉及式（I）的苯烷基胺衍生物或其生理上耐受的盐。 本发明涉及包含这种苯烷基胺衍生物的药物组合物，以及这种苯烷基胺衍生物用于治疗目的的用途。 酚烷基胺衍生物是GlyT1抑制剂。
-
6.发明申请AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权氨基嘌呤衍生物，含有它们的药物组合物及其在治疗中的使用
公开(公告)号：US20140031331A1
公开(公告)日：2014-01-30
申请号：US14031265
申请日：2013-09-19
Applicant: ABBOTT LABORATORIES , ABBVIE DEUTSCHLAND GMBH & CO KG
Inventor： Wilhelm Amberg , Michael Ochse , Udo Lange , Andreas Kling , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles W. Hutchins
IPC: C07C311/05 , C07D233/84 , C07D231/18 , C07D213/71 , C07D409/12 , C07D207/12 , C07D275/02 , C07D205/04 , C07D403/12 , C07D401/12 , C07C271/24 , C07D333/34
CPC classification number: C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/13 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07C2601/02 , C07C2601/04 , C07C2602/10 , C07D205/04 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D265/30 , C07D275/02 , C07D295/096 , C07D295/135 , C07D305/08 , C07D333/34 , C07D401/12 , C07D403/12 , C07D409/12 , C07F7/081
Abstract: The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.
Abstract translation: 本发明涉及式（I）的氨基四氢化萘衍生物或其生理上耐受的盐。 本发明涉及包含这种氨基四氢化萘衍生物的药物组合物，以及这种氨基四氢化萘衍生物用于治疗目的的用途。 氨基四氢叶酸衍生物是GlyT1抑制剂。
-
公开(公告)号：US20220169620A1
公开(公告)日：2022-06-02
申请号：US17537600
申请日：2021-11-30
Applicant: AbbVie Deutschland GmbH & Co. KG
Inventor： Willie Amberg , Gisela Backfisch , Karen Bodié , Katja Hempel , Loic Laplanche , Mario Mezler , Michael Ochse , Sean Turner , Jeroen van Bergeijk , Elizabeth van der Kam
IPC: C07D265/34
Abstract: The present invention is directed to spiro-cyclic amine derivatives which are modulators of S1P receptors and are useful in the treatment of CNS disorders.
-
公开(公告)号：US20170174672A1
公开(公告)日：2017-06-22
申请号：US15388516
申请日：2016-12-22
Applicant: AbbVie Deutschland GmbH & Co. KG
Inventor： Wilhelm Amberg , Udo Lange , Herve Geneste , Michael Ochse , Ralf Biesinger , Frank Oellien
IPC: C07D413/12 , C07D205/04 , C07C229/48 , C07C229/46 , C07D211/62 , C07D261/12 , C07D209/52 , C07D207/16 , C07D207/08 , C07D265/36 , C07C59/72 , C07D405/04 , C07D311/04
CPC classification number: C07D413/12 , C07C59/72 , C07C229/30 , C07C229/36 , C07C229/46 , C07C229/48 , C07C229/50 , C07C2601/04 , C07C2601/14 , C07C2602/10 , C07C2602/38 , C07D205/04 , C07D207/06 , C07D207/08 , C07D207/16 , C07D209/52 , C07D209/94 , C07D211/32 , C07D211/62 , C07D261/12 , C07D265/36 , C07D265/38 , C07D311/04 , C07D311/58 , C07D405/04 , C07D405/14
Abstract: The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
-
公开(公告)号：US09163019B2
公开(公告)日：2015-10-20
申请号：US14208067
申请日：2014-03-13
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Hervë Geneste , Michael Ochse , Karla Drescher , Berthold Behl , Loic Laplanche , Jürgen Dinges , Clarissa Jakob
IPC: A61K31/54 , C07D471/02 , C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims.The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
Abstract translation: 本发明涉及式I化合物，N-氧化物，互变异构体，前药及其药学上可接受的盐：在式I中，变量Het，A，X，Y，Z，R1，R2，R3，R4， R5和Q如权利要求中所定义。 式I化合物，N-氧化物，互变异构体，其前药和药学上可接受的盐是10A型磷酸二酯酶的抑制剂。 因此，本发明还涉及式I化合物，N-氧化物，互变异构体，前药和其药学上可接受的盐在制备药物中的用途，因此其适用于治疗或控制医学病症 选自神经障碍和精神障碍，用于改善与这种障碍相关的症状并降低这种障碍的风险。
-
10.发明申请5-RING HETEROAROMATIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS 审中-公开5环异构体化合物及其作为5-HT5受体的结合合作伙伴使用
公开(公告)号：US20150183770A1
公开(公告)日：2015-07-02
申请号：US14584902
申请日：2014-12-29
Applicant: ABBVIE DEUTSCHLAND GMBH & CO. KG
Inventor： Wilhelm Amberg , Astrid Netz , Andreas Kling , Michael Ochse , Udo Lange , Andreas Haupt , Francisco Javier Garcia-Ladona , Wolfgang Wernet (Deceased)
IPC: C07D417/04 , C07D231/38 , C07D405/04 , C07D409/04 , C07D413/04 , C07D233/88 , C07D249/14
CPC classification number: C07D417/04 , C07D231/38 , C07D233/70 , C07D233/88 , C07D249/14 , C07D405/04 , C07D409/04 , C07D413/04
Abstract: The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for the treatment and/or prevention of diseases, and medicaments containing same.
Abstract translation: 本发明涉及通式（I）的5-环杂芳族化合物，其用于治疗和/或预防疾病的用途，以及含有它们的药物。
